N6-Methyladenosine Regulator-Mediated Immune Patterns and Tumor Microenvironment Infiltration Characterization in Glioblastoma

Wu Xiong¹,²†, Cong Li¹,²†, Bowen Wan³†, Ziyang Zheng¹,², Yingfei Zhang¹,², Siming Wang¹,² and Jin Fan¹,²*

¹ Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, ² Nanjing Medical University, Nanjing, China, ³ Department of Orthopaedics, Subei People’s Hospital of Jiangsu, Clinical Medical College of Yangzhou University, Yangzhou, China

Background: Epigenetic modifications, according to emerging evidence, perform a critical role for cellular immune response and tumorigenesis. Nonetheless, the role of N6-methyladenosine modification in shaping the glioblastoma tumor microenvironment is unknown.

Methods: N6-methyladenosine(m6A) methylation patterns in GBM patients were evaluated via multiple omics analysis of 15 m6A regulators and systematically correlated with tumor immune features. For quantification of N6-methyladenosine methylation patterns of individual patients, GM-score was developed and correlated with clinical and immunological characteristics.

Results: Glioblastoma has two different m6A methylation patterns that are strongly associated with TME characteristics, tumor subtype, immunotherapy response, and patient prognosis. High-GM-score is associated with an immune tolerance phenotype dominated by the IDH1 wild molecular subtype and the Mesenchymal tissue subtype, as well as a high infiltration of immune cells and stromal cells and a poor prognosis. Furthermore, despite higher immune checkpoint expression, individuals with a high-GM-score have a poorer response to anti-CTLA4 immunotherapy regimens due to T-cells dysfunctional. Low-GM-score individuals had an immunodeficient phenotype dominated by IDH mutant molecular subtypes and Proneural tissue subtypes, with less immune cell infiltration and a better prognosis. Furthermore, patients with low-GM-scores had higher microsatellite instability (MSI) and t-cell exclusion scores, as well as a better response to anti-CTLA4 immunotherapy regimens.

Conclusion: This study demonstrated that m6A modification patterns play an important role in the shaping of TME complexity and diversity. The GM-score could identify m6A modification patterns in individual patients, resulting in a more personalization and efficacious anti-tumor immunotherapy strategy.

Keywords: m6A, glioblastoma, tumor microenvironment, immunotherapy, biomark
INTRODUCTION

Epigenetic modifications, according to emerging evidence, play a critical role in cellular immune response and tumorigenesis (1). As the most common post-transcriptional modification of RNA, m6A methylation modificationization has recently become a key area of cancer research. The m6A methylation post-transcriptionally influences various biological processes, including RNA processing, splicing, stabilization, translation, and degradation (2, 3). Moreover, m6A methylation is a dynamic, reversible modification process governed by writers, readers and erasers (4, 5). Writers (methyltransferases) such as WTAP, METTL3, RBM15 and ZC3H13, create m6A marks (6). Erasers, mainly FTO, are demethylases (7). Readers, which include YTHDCs, HNRNPC, FMR1 and IGF2BPs, detect and bind m6A modification sites to create equivalent signals (8).

The tumor microenvironment (TME) performs a major effect on cancer progression, according to growing evidence (9). Cancerous cells, mesenchymal cells, infiltrating leukocytes, and secretory factors make up the tumor microenvironment, and it offers a fresh look at tumorigenesis (10). The understanding of the TME landscape grows in tandem with the diversity and complexity of the TME landscape. TME appears to make a significant contribution in the procedure and immunotherapeutic reaction in tumorigenesis, according to a large body of evidence (11). Immunotherapy reactivates the anti-tumor immune response by blocking co-inhibitory receptors (12). Immunotherapy is effective in glioblastoma, but its efficacy has been inconsistent due to a lack of systematic understanding of the glioblastoma TME. As a result, a thorough understanding of TME’s heterogeneity and complexity is critical for identifying new therapeutic targets and evaluating immunotherapeutic response.

In recent years, the role of m6A methylation in TME has received increasing attention (13). For example, m6A methylation can control T-cell homeostasis (14). The antitumor effect of dendritic cells is regulated by mRNA m6a methylation and YTHDF1 (15). Furthermore, studies suggest that m6A methylation influences immunotherapy (16, 17). ALKBH5, a common m6A demethylase, was discovered to modulate the anti-PD-1 therapeutic response by inhibiting the accumulation of immune cells in TME in a study by Li et al. (18). FTO may regulate melanoma response to immunotherapy (19). Nevertheless, Current studies on m6A methylation in glioblastoma are focus on individual m6A regulators and there is urgent need for an all-sided study of m6A-methylation modes in glioblastoma.

As a result, we used genomic data from six glioblastoma cohorts to evaluate m6A-methylation modes and correlate these patterns with TME infiltration traits in this study. We discovered two different m6A-methylation patterns and were surprised to discover that the TME features in these two patterns were very similar to immune tolerance and immunodeficiency phenotypes, respectively. Lasso analysis identified 14 prognosis-associated m6A methylation pattern signature genes. We generated a GM-score to evaluate the m6A-methylation patterns in individual patient using a principal component analysis (PCA) approach on the expression of the 14 m6A methylation pattern signature genes, demonstrating that m6A-methylation patterns contribute significantly in the characterization of the TME in glioblastoma. Briefly, our GM-score system enables more individualized and efficacious anti-tumor immunotherapy strategies by allowing us to identify TME infiltration features.

METHODS

Data Collection and Processing

Publicly available gene expression data and complete clinical annotations were obtained from GEO and TCGA. Patients whose survival information were unavailable were excluded and 6 eligible GBM cohorts (TCGA-GBM, GSE7696, GSE13041, GSE72951, GSE8300, GSE122586) selected for further analysis. The “ComBat” algorithm using the sva package corrected for batch effects due to non-biotechnical bias. RNAseq transcriptome data for healthy human tissues were retrieved from GTEx. The GTEx and TCGA datasets were combined and then reconciled using quantile normalization as well as svaeq-based batch effect removal. CNV data were retrieved from Xena. As previously reported, m6A regulator mutation rates and CNV frequencies were calculated (20–22). For validation purposes, CGGA transcript data can be downloaded from the CGGA website.

Immunohistochemistry

Immunohistochemistry results were obtained from the Human Protein Atlas (HPA) database (https://www.proteinatlas.org/). The Human Protein Atlas, one of the world’s most accessed biological databases, is a project to map the entire human proteome using proteomics and the integration of various other histological techniques. Immunohistochemical Average Optical Density values were measured with Image-Pro Plus6.

Unsupervised Consensus Clustering Based on 15 m6A Regulators

According to expression levels of 15 m6A regulators, including 4 writers (METTL3, WTAP, ZC3H13, RBM15B), 1 eraser (FTO), and 10 readers (YTHDC1, HNRNPAB1, YTHDC2, HNRNPC, YTHDF3, FMR1, IGFBP1, LRPPRC, IGFBP2, IGFBP3), unsupervised clustering analysis was used for identification of various m6A modification patterns and patient classification for further analyses. Cluster numbers and their stabilities were evaluated using a consistent clustering algorithm.

Gene Set Variation Analysis

Gene set “c2.cp.kegg.v6.2.symbols” was retrieved from the MSigDB and GSVA enrichment analysis used to identify different m6A methylation patterns using “GSVA” package on R, with adjusted $p<0.05$ indicating statistical significance. In non-parametric and unsupervised approaches, GSVA is used for estimation of pathway and biological process changes in gene expression datasets.
Estimation of TME Immune Trait
The enrichment fraction from ssGSEA analysis was used to indicate relative abundances of every TME-infiltrating cell per sample. The genomes used to mark every TME-infiltrating immune cell type were retrieved from Charoentong’s study, which annotated human immune cell subtypes, such as activated CD8 T-cells, activated dendritic cells, macrophages, natural killer T-cells, and regulatory T-cells. Immune checkpoint, EMT, Pan-F-TBRS were also included.

Construction of Glioblastoma m6A Scoring System
Based on 15 m6A regulators, patients were classified into 2 m6A methylation modification patterns. Identification of DEGs between the different patterns was done by Empirical Bayesian analysis using the limma package in R. Lasso analysis and univariate Cox regression analysis of DEGs were performed to identify prognosis-related m6A methylation pattern signature genes, which were then subjected to PCA to establish GM-score.

\[ \text{GM – score} = \sum (PC_{1} + PC_{2}) \]

Statistical Analysis
The limma R package was used to perform differential gene expression analysis. The Spearman method was used for correlation analysis. To compute composition differences, Pearson’s chi-square analysis was used. The Wilcoxon rank sum test was used to calculate the statistical difference between the two groups. The Kruskal–Wallis test was used for comparisons of more than two groups. R software was used for all statistical analyses.

RESULTS
Landscape of m6A Methylation Regulators in GBM
15 m6A methylation regulators (4 writers, 10 readers, and 1 eraser) were synthetically analyzed in this study. The graphical abstract of this research was depicted in Figure 1A. The overall design of this study is summarized in Figure S1A. Differential analysis of 15 m6A methylation regulators yielded that most regulatory factors were significantly differentially expressed in normal vs GBM tissues \((p<0.05, \text{Figure 1B})\), and 11 regulators showed significant differences in the 4 subgroups (classical, mesenchymal, neural and proneural, \text{Figures S2A–O}). We then looked into the properties of the 15 m6A methylation regulators in greater detail. The 15 m6A regulators were altered 5.85 percent of the time in the 393 samples (23 mutations). The highest mutation rate was found in ZC3H13, followed by RBM15B (Figure 1C). Analysis of CNV alterations frequency revealed widespread CNV alterations (especially deletions) in the 15 regulators. While, HNRNPA2B1 and FMR1 had high CNV amplification frequencies (Figure 1D). The chromosomal locations of the CNV alteration on m6A regulators is shown on Figure 1E. PCA showed that expression levels of the 15 m6A methylation regulators could clearly distinguish between GBM and normal samples (Figure 1F). The results of the above analysis revealed that there was significant heterogeneity in the expression of m6A regulators between normal and GBM samples, implying that an imbalance in the expression of m6A regulators performs a vital part in the development of GBM.

Protein Expression of m6A Regulators
Immunohistochemistry was used to confirm the differential expression of m6A regulators protein in normal brain tissue and glioblastoma. The expression of the remaining m6A regulators proteins, with the exception of HNRNPC and YTHDC1, was consistent with the above findings (\text{Figures S3A–J}).

Two m6A Methylation Patterns of GBM
Six GBM cohorts were incorporated into a meta-cohort for further investigation of the role of the m6A methylation regulators in GBM. K-M analysis revealed that multiple m6A regulators had significant correlations with overall survival (Figure S1B). The comprehensive landscape of m6A regulator interactions, their prognostic significance and regulator connection in GBM patients was shown by an m6A regulator network (\text{Figure S1C}). The correlation of regulator co-expression was then investigated and significant correlation found between METTL3 and other regulators. The highest correlation (0.81) was between METTL3 and YTHDC2 (Figure S1D). Furthermore, we discovered that the writer and reader genes were differentially expressed in high and low FTO-expressing subgroups (Figure S1E). These results suggest that the expression of m6A regulators is significantly correlated, and thus we should investigate the role of m6A methylation modifications in glioblastoma from a comprehensive standpoint.

The specific relationship between TME and m6A regulators was then investigated. We observed that m6A regulators were significantly related to immune cell infiltration, with IGFBP1 was significantly positively related to immune cell and stroma-associated pathways (\text{Figures 2A, B}). We further compared the TME of patients with high and low IGFBP1 expression. Patients with high IGFBP1 expression had significantly higher immune cell infiltration and stroma-associated pathway activity than patients with low IGFBP1 expression (\text{Figures 2C, D}). Thus, in the m6A pattern, IGFBP1 may play a significant role in shaping the tumor microenvironment. Patients with low IGFBP1 expression also had a better prognosis (\text{Figure 2E}). The above findings imply that the m6A regulators may be important in the creation of distinct m6A modification patterns and immune characteristics of GBM.

Unsupervised consensus clustering of the expression of the m6A methylation regulators was used to investigate the m6A methylation patterns of glioblastoma. The consensus distributions for k (1-9) are displayed on empirical CDF plots (\text{Figure S4A}). Considering the consensus matrix for the analysis, \(k=2\) was the best option. According to the consensus matrix, the unsupervised algorithm based on the 15 regulators clearly differentiated the samples, and each sample in a cluster had a strong association (\text{Figure 3A}). Therefore, based on expression...
levels of m6A methylation regulators, GBM patients were divided into 2 clusters (A and B). Further, we found that the prognoses for these patients markedly differed, with cluster A patients exhibiting better OS (Figure 3B).

**TME Features in the Two m6A Clusters**

GSVA enrichment analysis of biological behavior differences between the 2 clusters showed that stromal as well as immune activation pathways like ECM receptor interactions, TGFβ signaling, cytokine-cytokine receptor interaction, cell adhesion chemokine signaling, T-cell receptor signaling, and Toll-like receptor signaling were significantly enriched in m6A cluster B (Figure 3C). While immune-related biological processes are lowly expressed in m6A cluster A (Figure 3C). Moreover, common immune functions like APC co stimulation, proinflammation, and type II IFN response are lower in m6A cluster A patients (Figure 3D). To elucidate the relationship between the m6A clusters and GBM immune traits, we analyzed infiltrating immune cells in every cluster. Surprisingly, m6A cluster B contains almost all adaptive and innate immune cells, with the exception of activated B cells, eosinophils, monocytes, and Th17 cells (Figure 3E). While patients in m6A cluster B did not show a corresponding survival advantage. Previous research has revealed that stromal cells in tumors play an immune-regulatory role (23). On the one hand, stromal cells can prevent immune cells from entering the tumor parenchyma. Stromal cells, on the other hand, can inhibit the function of T cells to kill tumor cells (21). Furthermore, tumor cells and stromal cell-driven angiogenesis have been shown to promote tumor metastasis (24). GSVA analysis results revealed...
significantly enhanced activity of stroma-related pathways in m6A cluster B (Figure 3C). As a result, we hypothesize that stromal activation in cluster B is the primary cause of immunosuppression and poor prognosis in glioblastoma. Subsequent analysis showed that stroma-related activities like angiogenesis, EMT, and Pan F TBRS were significantly enhanced in cluster B, which confirmed our speculation (Figure 3F). Taken together, we found that in GBM, the 2 m6A modification patterns have notably different TME cell infiltration characteristics. Cluster A was an immunodeficient phenotype exhibiting fewer immune cells and lower immune activity, while cluster B was an immune tolerance phenotype exhibiting increased immune cell infiltrations as well as stromal activation.

**Clinical Traits and Validation in the m6A Modification Patterns**

The traits of m6A-methylation patterns in distinct clinical features and biological behaviors were then investigated. Patients with the IDH1 mutant subtype mainly exhibited an immunodeficiency pattern in m6A cluster A, whereas patients with the IDH1 wild subtype were characterized by an immune tolerance pattern in m6A cluster B (Figure S4B). Furthermore,
tumors with the m6A cluster A had better differentiation and were more likely to be proneural or neural in nature. While the m6A cluster B pattern had poorer tumor differentiation and was enriched in Mesenchymal and Classical subtypes (Figure S4C). IDH1 mutation molecular subtypes and Proneural histological types were significantly associated with better survival in glioblastoma, whereas IDH1 wild molecular subtypes and Mesenchymal histological types were significantly associated with worse clinical outcome (25, 26). Tumors with m6A cluster B had stromal activation, were highly malignant, and progressed quickly. These results again confirmed that m6A methylation is significantly associated with stromal activation.

To validate the accuracy of the m6A methylation pattern classification, 373 glioblastoma patients from the CGGA database were chosen. Unsupervised clustering discovered two completely different m6A modification patterns in CGGA cohort, similar to meta cohort clustering (Figure S4D). Similarly, m6A cluster B in CGGA has increased immune infiltration and stromal activation, as well as a poor prognosis (Figures S4E–G). The above results verified the accuracy of m6A methylation pattern classification.

**Characteristics of m6A Related Phenotypes**

To further analyse the underlying biological processes of the two m6A modification patterns, we identified 58 DEGs associated with the m6A phenotype using the limma package (Figure 4A). GO and KEGG pathway enrichment analyses of the DEGs surprisingly showed that they were enriched in stromal activation pathways, confirming that m6A methylation modifications are closely linked to TME regulation (Figures 4B, C). To further validate the regulatory mechanism.
of m6A methylation modification in the tumor microenvironment of glioblastoma, we first performed Lasso analysis on 58 DEGs to obtain 41 signature genes of m6A methylation pattern, and then classified patients into different gene-clusters based on unsupervised clustering analysis of these genes (Figure 4D and Table S1). Consistent with cluster grouping of m6A methylation regulators, unsupervised clustering algorithm classified GBM patients into 2 classes based on these signature genes, which were named m6A gene-clusters A and B (Figure S5A). These results demonstrated that glioblastoma does have two different m6A methylation modification patterns.

Most m6A regulators were expressed differently in the two gene-clusters, which is in line with the m6A methylation pattern’s outcomes (Figure S5B). Similarly, the IDH1 mutation molecular subtype and the better differentiated Proneural tissue subtype were predominantly enriched in gene-cluster A, whereas the IDH1 wild molecular subtype and the poorly differentiated Mesenchymal tissue subtype were predominantly enriched in gene-cluster B (Figures S5C, D).
gene-cluster A had a better prognosis than gene-cluster B, which is also in line with the m6A methylation pattern’s expected outcomes (Figure 5SE).

To verify the relevance of m6A-related phenotypes to the tumor microenvironment, we analyzed the expression of common TME signatures in 2 m6A gene-clusters. Gene-cluster B had significantly higher stromal activity, as evidenced by the upregulation of angiogenesis and EMT signatures (Figure 4E). Meanwhile, immune activation-related signatures like Antigen processing machinery and CD8 effects also were found in abundance in gene-cluster B. These results suggest that the B gene-cluster Belongs to the immune tolerant phenotype. The expression of common immune activation genes and immune cell infiltration in the two gene-clusters was then compared (Figures 4F, G). The findings confirmed that gene-cluster B is immune tolerant phenotype and gene-cluster A is immunodeficient phenotype. These analyses again indicated that m6A methylation has a vital role in shaping the tumor microenvironment of GBM.

Construction of Quantitative Model of m6A Methylation Modification Patterns in Individual Patients

The analyses above were done on patient populations. Next, we sought to precisely quantify m6A methylation patterns in individual patients. Based on the univariate Cox analysis of 41 m6A methylation pattern signature genes, we obtained 14 prognosis-related signature genes (Table S2). Based on the 14 prognosis-related m6A methylation pattern signature genes, we created a glioblastoma m6A scoring system (GM-score) by PCA to assess m6A methylation modifications in individual patients. This scoring system takes full account of individual patient heterogeneity and can effectively assess patients’ m6A methylation patterns. Patients were assigned into high- and low-GM-score subgroups based on median score. The Alluvial diagram revealed the variation of m6A cluster, gene-cluster and GM-score in individual patients and also demonstrated the consistency and reliability of our analysis results (Figure 5A). The GM-score of gene-cluster B was higher than that of gene-cluster A, implying that the high score is linked to immune and stromal activation signals (Figure 5B). Importantly, the GM-score of m6A cluster B was also higher than that of m6A cluster A (Figure 5C). Further investigation revealed that high scores were indeed related to increased stromal activity and immune infiltration (Figures 5D, E). Furthermore, patients with the Mesenchymal subtype had a higher GM-score than patients with the other three tissue subtypes (Figure 5F). These observations imply that having a high-GM-score is associated with immune and stromal activation. GM-score can better assess the m6A methylation modification pattern in individual patients and further evaluate the TME characteristics to distinguish the nature of immunosuppression in individual patients.

Following that, we attempted to identify the utility of GM-score in predicting patients’ prognosis. Patients with low-GM-score had higher survival rates and longer survival periods than patients with high-GM-score, according to Kaplan-Meier OS curves (Figure 5G). We calculated the GM-score of GBM patients in the CGGA database and divided them into high and low subgroups based on the same median to test the model’s reliability and stability. Patients with a low-GM-score had a better prognosis, according to the findings (Figure 5H). We verified if GM-score could be used as a standalone prognostic biomarker for glioblastoma. A multivariate Cox analysis that included age, gender, IDH1 status, and histological type confirmed GM-score as a reliable and independent marker for determining prognosis (Figure 5I).

GM-Score in the Role of Immunotherapy

Because TCGA-GBM patients have complete immunotherapy information, we investigated the role of GM-score in predicting immunotherapy response in the TCGA cohort. TIDE was used to predict immunotherapy response in different GM-score subgroups. Patients with high TIDE scores had a lower response to immunotherapy, indicating that immunotherapy was less likely to benefit them (27). TIDE scores were lower in the low-GM-score subgroup than in the high-GM-score subgroup, implying that ICI treatment may benefit patients in the low-GM-score subgroup more (Figure 6A). To verify this conclusion, we compared the effect of anti-CTLA4 and anti-PD1 treatment on different GM-score subgroups (Figure 6B). The anti-CTLA4 treatment works better in patients with low-GM-scores, whereas anti-PD1 immunotherapy doesn’t show a similar result.

To determine the cause of the differences in immunotherapy response, we compared microsatellite instability (MSI), T-cell exclusion, and T-cell dysfunction scores between the two subgroups. The low-GM-score subgroup had higher scores for microsatellite instability (MSI) and T-cell exclusion, whereas the high-GM-score subgroup had higher scores for T-cell dysfunction (Figures 6C–E). In addition, ROC analysis revealed that the AUC values of GM-score reached 0.650 at 1 year, 0.617 at 2 years, and 0.710 at 3 years (Figure 6F).

DISCUSSION

As the most common type of epigenetic modification, m6A methylation modifications may play a vital role in shaping of the tumor microenvironment (28). Most studies, however, have focused on the role of single m6A regulators in tumors, and the role of m6A methylation modifications in tumor development has rarely been evaluated holistically. We systematically described TME cell infiltration mediated by the combined action of multiple m6A regulators, as well as the corresponding modification patterns, in this study. Actually, two distinct m6A modification patterns have been identified as important in shaping the TME landscape. Furthermore, a scoring system known as GM-score was developed to correlate individual patients’ m6A modification patterns with their immunotherapy response, offering a clinical instrument for a more personalized and efficient antitumor immunotherapeutic strategy.
Herein, we initially assessed the expression levels, somatic mutations, and copy number changes of 15 m6A regulators in glioblastoma patients and discovered that 14 m6A regulators had differential expression. Among all m6A regulators, ZC3H13 had the highest mutation frequency. Furthermore, the majority of the m6A regulators had copy number changes. These findings imply that an imbalance in the expression of m6A regulators may play an important role in the development of GBM. Huang et al. discovered that YTHDF2 promotes aggressive glioblastoma growth (29). Chen’s research suggests that m6A regulators contribute to malignant progression and have an effect on glioblastoma clinical prognosis (30). The correlation between m6A regulators and glioblastoma tumor microenvironment infiltrating cells, however, remains unknown. As a result, we investigated the correlation between the 15 regulators and glioblastoma tumor microenvironment. We discovered a

---

**FIGURE 5** | Construction of glioblastoma m6A scoring system (GM-score). (A) Alluvial diagram of GBM patient m6A cluster, m6A gene-cluster, and GM-score. (B) GM-score of the two m6A gene clusters. (C) GM-score of the two m6A clusters. (D) Degree of enrichment of stromal activation pathways in 2 GM-score subgroups. (E) Immune cell abundance in the 2 GM-score subgroups. (F) Differences in GM-score between various GBM subtypes. (G) Kaplan-Meier OS analysis of 2 GM-score subgroups in meta_cohort. (H) Kaplan-Meier OS analysis of 2 GM-score subgroups in CGGA cohort. (I) Independent prognostic analysis of GM-score. *, **, and *** indicate p = < 0.05, < 0.01, and < 0.001, respectively.
strong relationship between these regulators and glioblastoma tumor microenvironment immune infiltrating cells, with IGFBP1 being significantly positively correlated with most immune cells and stroma-associated pathways, implying a potential role of m6A methylated modification in the formation of tumor microenvironment in glioblastoma.

Through unsupervised clustering analysis of expression of 15 m6A regulators, we developed 2 distinct m6A methylation modification patterns in glioblastoma and labeled them m6A clusters A and B. TME cell infiltration analysis, to our surprise, revealed that m6A cluster B was comparatively enriched in innate immune cell infiltration, such as monocytes, macrophages, and dendritic cells, and also adaptive immune cell infiltration. Patients with m6A cluster B, however, did not have a corresponding survival advantage. Previous research has demonstrated that stromal cells play an immunomodulatory role in tumors (31). On the one hand, stromal cells can keep immune cells out of the tumor parenchyma (21). Stromal cells, on the other hand, can prevent T cells from killing tumor cells (24). Furthermore, tumor cells and stromal cell-driven angiogenesis have been linked to tumor metastasis. As a result, we hypothesized that activation of stroma in cluster B inhibited immune cell anti-tumor effects. Several studies have found that inflammatory infiltration by tumor-associated macrophages promotes glioblastoma growth and metastasis, resulting in a poor prognosis (32). Importantly, the interaction of tumor-associated macrophages with stromal cells contributes to the formation of the tumor microenvironment (33). As a result,
therapies that target tumor-associated macrophages may improve patient prognosis (34). Cluster A had less immune cell infiltration, including both intrinsic and adaptive immune cells, than cluster B. Not surprisingly, survival in cluster B was lower due to suppression of innate and adaptive immunity, but it was higher in comparison to cluster A. The GSEA analysis revealed that the two m6A modification patterns followed significantly different pathways. ECM receptor interaction, TGF signaling, cytokine-cytokine receptor interaction, cell adhesion chemokine signaling, t-cell receptor signaling, and toll-like receptor signaling were all significantly enriched in m6A cluster B. Moreover, we discovered that IDH1 mutant molecular subtype and proneural tissue subtype dominated m6A cluster A, whereas IDH1 wild subtype mesenchymal tissue subtype dominated m6A cluster B. We repeated the analysis on the CGGA cohort to confirm the accuracy of m6A methylation pattern classification and obtained the same results.

Following that, a Lasso analysis of DEGs between m6A methylation modification patterns identified 41 m6A pattern signature genes that may be mediated as post-transcriptional modification products by m6A regulators. Similar to the m6A modification pattern clustering results, two gene-clusters were associated with different TME-infiltrating cells, tumor subtypes, and prognosis. The complexity of m6A modification patterns in individual patients necessitates a novel approach to quantifying m6A modification patterns. As a result, we developed the GM-score scoring system, which is based on 14 prognostically relevant m6A methylation pattern signature genes, to assess m6A methylation patterns in glioblastoma. Furthermore, the two GM-score subgroups have distinguishable TME infiltrative characteristics. In other words, the high-GM-score subgroup had more immune cells and higher stromal activity, whereas the low-GM-score subgroup had less immune cell infiltration. The low-GM-score subgroup had a higher survival rate and a longer survival than the high-GM score subgroup, according to survival analysis. These findings suggest that the GM-score is a reliable and effective tool for clinical assessment of m6A modification patterns in individual patients, and that it can be used to assess the trait of TME-infiltrating cells in patients to indicate immunotherapy response.

Immunotherapy is effective in glioblastoma, but its efficacy has been inconsistent due to a lack of systematic knowledge of the immune milieu in GBM and the inability to assess individual patients’ immune status. TIDE was used to assess immunotherapy responsiveness in different GM-score subgroups. Patients in the high-GM-score subgroup had higher TIDE and T-cell dysfunction scores than patients in the low-GM-score subgroup, implying that their lower immunotherapy response could be due to immune evasion caused by T-cell dysfunction. The low-GM-score subgroup had higher MSI and lower TIDE scores than the high-GM-score subgroup, indicating less immune evasion and higher MSI. MSI-induced high mutational load has been shown to make tumors immunogenic and susceptible to immune checkpoint inhibitors (35–37). We directly compared the effect of anti-CTLA4 and anti-PD1 treatment on different GM-score subgroups. The anti-CTLA4 treatment works better in patients with low-GM-scores, whereas anti-PD1 immunotherapy doesn’t show a similar result. A study by Spencer et al. showed that anti-PD-1 primarily promotes the expansion of exhausted-like CD8 T-cell subpopulations in tumor infiltrates, whereas anti-CTLA-4 promotes the expansion of ICOS+ Th1-like CD4 T cells on top of that (38). We believe this may explain why anti-CTLA4 treatment works better in patients with low GM scores, whereas PD1/PD-L1 immunotherapy does not. Our research serve as the basis and provide a blueprint for better understanding patients’ antitumor immune responses, which can then be used to guide more personalized and efficient immunotherapy strategies.

Briefly, GM-score can systematically assess individual patients’ m6A methylation modification pattern and corresponding tumor microenvironment features in order to further determine the tumor’s immunophenotype and guide more effective clinical practice. Patients’ clinicopathological characteristics, such as histological subtypes, molecular subtypes, genetic variants, and MSI status, can also be assessed using GM-score. GM-score can also be used as a stand-alone prognostic biomarker to anticipate survival outcomes. The GM-score can also be used to predict patient response to anti-CTLA4 immunotherapy. More significantly, this research provided new insights into cancer immunotherapy by altering m6A modification patterns by targeting m6A regulators or m6A methylation pattern signature genes, reverting unfavorable cellular infiltration characteristics and converting cold tumors to hot tumors, which could aid in the development of new drug combination strategies or immunotherapeutic agents. Our research suggests new ways to improve patients’ clinical responses to immunotherapy, identify distinct tumor immune phenotypes, and promote tumor-specific immunotherapy.

CONCLUSION

This study demonstrated that m6A modification patterns play an important role in the shaping of TME complexity and diversity. The GM-score could identify m6A modification patterns in individual patients, resulting in a more personalization and efficacious anti-tumor immunotherapy strategy.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

This piece was created by JF, WX, CL and BW combined and analyzed the data. This manuscript was written by ZZ, YZ and SW. All authors contributed to the article and approved the submitted version.
This study was funded by the Natural Science Foundation of China (81772352), Changjiang Scholars Program (KY216R202103), Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX21_1613, KYCX20_1434).

ACKNOWLEDGMENTS

Thanks to TCGA, GEO, GTEx, ImmPort and InnateDB database for their work.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.819080/full#supplementary-material

REFERENCES

1. Dawson MA, Kouzarides T. Cancer Epigenetics: From Mechanism to Therapy. Cell (2012) 150:12–27. doi: 10.1016/j.cell.2012.06.013
2. He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-Methyladenosine and its Role in Cancer. Mol Cancer (2019) 18:176. doi: 10.1186/s12943-019-1109-9
3. Wu Z, Shi Y, Lu M, Song M, Yu Z, Wang J, et al. METTL3 Counteracts Premature Aging via M6a-Dependent Stabilization of Msi12 mRNA. Nucleic Acids Res (2020) 48:11083–96. doi: 10.1093/nar/gkaa816
4. Fu Y, Dominissini D, Rechavi G, He C. Gene Expression RegulationMediated Through Reversible M(6)A RNA Methylation. Nat Rev Genet (2014) 15:293–306. doi: 10.1038/nrg3724
5. Liu ZX, Li LM, Sun HL, Liu SM. Link Between M6a Modifiers and M6a-Dependent Stabilization of Msi12 mRNA. Nucleic Acids Res (2020) 48:11083–96. doi: 10.1093/nar/gkaa816
6. Lan Q, Liu PY, Haase J, Bell JL, Hüttelmaier S, Liu T. The Critical Role of RNA M(6)A Methylation in Cancer. Cancer Res (2019) 79:1285–92. doi: 10.1158/0008-5472.CAN-18-2965
7. Zhu ZM, Huo FC, Pei DS. Function and Evolution of RNA N6-Methyladenosine Modification. Int J Biol Sci (2020) 16:1929–40. doi: 10.7150/ijbs.45231
8. Meyer KD, Jaffrey SR. The Dynamic Epitranscriptome: N6-Methyladenosine and Gene Expression Control. Nat Rev Mol Cell Biol (2014) 15:131–26. doi: 10.1038/nrm3785
9. Quail DF, Joyce JA. Microenvironmental Regulation of Tumor Progression and Metastasis. Nat Med (2013) 19:1423–37. doi: 10.1038/nm.3394
10. Gao Y, Wang H, Li H, Ye X, Xia Y, Yuan S, et al. Integrated Analyses of M(1)A Regulator-Mediated Modification Patterns in Tumor Microenvironment-Inflicting Immune Cells in Colon Cancer. Oncoimmunology (2021) 10:1936758. doi: 10.1080/2162402X.2021.1936758
11. Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, et al. Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy. Cancer Lett (2020) 470:126–33. doi: 10.1016/j.canlet.2019.11.009
12. Schnell A, Bod L, Madi A, Kuchroo VK. The Yin and Yang of Co-Inhibitory Receptors: Toward Anti-Tumor Immunity Without Autoimmunity. Cell Res (2020) 30:285–99. doi: 10.1038/s41422-020-0277-x
13. Li R, Yin YH, Ji XL, Liu X, Li JP, Qu YQ, et al. Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers. Front Mol Biosci (2021) 8:64620. doi: 10.3389/fmolb.2021.64620
14. Li HB, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, et al. M(6)A mRNA Methylation Controls T Cell Homeostasis by Targeting the IL-7/STAT5/ SOCS Pathways. Nature (2017) 548:338–42. doi: 10.1038/nature23450
15. Han D, Liu J, Chen C, Dong L, Liu Y, Cao Q et al. Anti-Tumour Immunity Controlled Through mRNA M(6)A Methylation and YTHDF1 in Dendritic Cells. Nature (2019) 566:270–4. doi: 10.1038/s41586-019-0916-x
16. Wang L, Hui H, Agrawal K, Yang J, Li N, Tang R, et al. M(6)A RNA Methyltransferases METTL3/14 Regulate Immune Responses to Anti-PD-1 Therapy. EMBO J (2020) 39:e104514. doi: 10.15252/embj.2020104514
17. Shriwas O, Mohapatra P, Mohanty S, Dash R. The Impact of M6a RNA Methylation in Therapy Resistance of Cancer: Implication in Chemo-therapy, Radiotherapy, and Immunotherapy. Front Oncol (2020) 10:612337. doi: 10.3389/fonc.2020.612337
18. Li N, Kang Y, Wang L, Hui H, Sun H, Tan R, et al. ALKBH5 Regulates Anti-PD-1 Therapy Response by Modulating Lactate and Suppressive Immune Cell Accumulation in Tumor Microenvironment. Proc Natl Acad Sci USA (2020) 117:20159–70. doi: 10.1073/pnas.1918986117
19. Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, et al. M(6)A mRNA Demethylase FTO Regulates Melanoma Tumorigenicity and Response to Anti-PD-1 Blockade. Nat Commun (2019) 10:2872. doi: 10.1038/s41467-019-10669-9
20. Li Y, Gu J, Xu F, Zhu Q, Chen Y, Ge D, et al. Molecular Characterization, Biological Function, Tumor Microenvironment Association and Clinical Significance of M6a Regulators in Lung Adenocarcinoma. Brief Bioinform (2021) 22(4):bbaa225. doi: 10.1093/bib/bbaa225
21. Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. M(6)A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Gastric Cancer. Mol Cancer (2020) 19:53. doi: 10.1186/s12943-020-01170-0
22. Song W, Ren J, Xiang R, Kong C, Fu T. Identification of Pyroptosis-Related Subtypes, the Development of a Prognosis Model, and Tumor Microenvironment Infiltration in Colorectal Cancer. Oncoimmunology (2021) 10:20197636. doi: 10.2080/2162402X.2021.1978756
23. Chen DS, Dellman I. Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature (2017) 541:321–30. doi: 10.1038/nature21349
24. Moserle L, Csanovas O. Anti-Angiogenesis and Metastasis: A Tumour and Stromal Cell Alliance. J Intern Med (2013) 273:128–37. doi: 10.1111/j.1365-2796.2012.01208
25. Jiang D, Gong F, Ge X, Lv C, Huang C, Feng S, et al. Neuron-Derived Exosomes-Transmitted miR-124-3p Protect Traumatically Injured Spinal Cord by Suppressing the Activation of Neurotoxic Microglia and Astrocytes. *J Nanobiotechnol* (2020) 18:105. doi: 10.1186/s12951-020-00665-8

26. Barnes JM, Kaushik S, Bainer RO, Sa JK, Woods EC, Kai F, et al. A Tension-Mediated Glycocalyx-Integrin Feedback Loop Promotes Mesenchymal-Like Glioblastoma. *Nat Cell Biol* (2018) 20:1203–14. doi: 10.1038/s41556-018-0183-3

27. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T Cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response. *Nat Med* (2018) 24:1550–8. doi: 10.1038/s41591-018-0136-1

28. Dong Z, Cui H. The Emerging Roles of RNA Modifiers in Glioblastoma. *Cancers (Basel)* (2020) 12(3):736. doi: 10.3390/cancers12030736

29. Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, et al. EGFR/SRC/ERK-Stabilized YTHDF2 Promotes Cholesterol Dysregulation and Invasive Growth of Glioblastoma. *Nat Commun* (2021) 12:177. doi: 10.1038/s41467-020-20379-7

30. Du J, Hou K, Mi S, Ji H, Ma S, Ba Y, et al. Malignant Evaluation and Clinical Prognostic Values of M6a RNA Methylation Regulators in Glioblastoma. *Front Oncol* (2020) 10:208. doi: 10.3389/fonc.2020.00208

31. Galland S, Stamenkovic I. Mesenchymal Stromal Cells in Cancer: A Review of Their Immunomodulatory Functions and Dual Effects on Tumor Progression. *J Pathol* (2020) 250:555–72. doi: 10.1002/path.5357

32. Shi Y, Ping YF, Zhou W, He ZC, Chen C, Bian BS, et al. Tumour-Associated Macrophages Secrete Pleiotrophin to Promote PTPRZ1 Signalling in Glioblastoma Stem Cells for Tumour Growth. *Nat Commun* (2017) 8:15080. doi: 10.1038/ncomms15080

33. Umakoshi M, Takahashi S, Itoh G, Kuriyama S, Sasaki Y, Yanagihara K, et al. Macrophage-Mediated Transfer of Cancer-Derived Components to Stromal Cells Contributes to Establishment of a Pro-Tumor Microenvironment. *Oncogene* (2019) 38:2162–76. doi: 10.1038/s41388-018-0564-x

34. Poon CC, Sarkar S, Yong VW, Kelly JP. Glioblastoma-Associated Microglia and Macrophages: Targets for Therapies to Improve Prognosis. *Brain* (2017) 140:1548–60. doi: 10.1093/brain/aww355

35. Baretti M, Le DT. DNA Mismatch Repair in Cancer. *Pharmacol Ther* (2018) 189:45–62. doi: 10.1016/j.pharmthera.2018.04.004

36. Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, et al. Tumor Mutational Burden is Predictive of Response to Immune Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer. *Ann Oncol* (2019) 30:1096–103. doi: 10.1093/annonc/mdz134

37. Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, et al. Immune Checkpoint Inhibitors for the Treatment of MSI-H/MMR-D Colorectal Cancer and a Perspective on Resistance Mechanisms. *Br J Cancer* (2019) 121:809–18. doi: 10.1038/s41416-019-0599-y

38. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. *Cell* (2017) 170:1120–33.e17. doi: 10.1016/j.cell.2017.07.024

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xiong, Li, Wan, Zheng, Zhang, Wang and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.